{
    "nct_id": "NCT04450069",
    "official_title": "A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies",
    "inclusion_criteria": "* Patients with relapsed / refractory previously treated B cell malignancies (according to the World Health Organization classification; 2017)\n* Patients must have received adequate prior therapy including at least two lines of prior therapies including anthracycline or bendamustine-containing chemotherapy, anti-CD20 (cluster of differentiation antigen 20) therapies and/or Brutton's tyrosine kinase (BTK) inhibitors\n* Patients treated with prior CD19 targeted molecules (e.g., Blincyto) must have confirmed CD19+ disease\n* Patients must be ineligible for allogeneic stem cell transplant (SCT)\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1\n* Estimated life expectancy of ≥ 12 weeks from the first day of SWI019 dose administered\n* Willing to undergo pre- and post-treatment core needle biopsy\n* Adequate hematological, renal, pulmonary, cardiac, and liver function\n* Resolved adverse events of any prior therapy to either baseline or CTCAE Grade ≤1\n* Women of childbearing potential, a negative pregnancy test and must agree to practice effective birth control\n* Men sexually active with female partners of child bearing potential must agree to practice effective contraception\n* Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other procedures\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients diagnosed with certain disease histologies including pediatric lymphomas/leukemias, monoclonal gammopathy of undetermined significance (MGUS), T-cell histiocyte large B cell lymphoma\n* Pregnant or lactating women\n* Active bacterial, viral, and fungal infections\n* History of allogeneic stem cell transplantation\n* Treatment with any prior lentiviral or retroviral based CAR-T\n* Patients receiving live (attenuated) vaccines within 4 weeks of screening visit or need for live vaccine on study\n* Patients with known active central nervous system (CNS) disease. Patients with prior CNS disease that has been effectively treated may be eligible\n* History of Class III or IV New York Heart Association (NYHA) heart failure, myocardial infarction, unstable angina or other significant cardiac disease within 6 months of screening\n* Involvement of cardiac tissue by lymphoma\n* Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP)\n* HIV-1 and HIV-2 antibody positive patients",
    "miscellaneous_criteria": ""
}